Last updated on August 2019

The Effect Of Lifitegrast On Refractive Accuracy And Symptoms In Dry Eye Patients Undergoing Cataract Surgery


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Dry eye syndrome
  • Age: - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  1. Patients with planned cataract surgery
  2. Central or inferior corneal fluorescein staining defined by the Oxford Scale
  3. Reduced tear break up time (TBUT) 10 seconds.
  4. Able to comprehend and sign a statement of informed consent.
  5. Willing and able to complete all required postoperative visits.

Exclusion Criteria:

  1. Ocular surgery (e.g., intraocular, oculoplastic, corneal or refractive surgical procedure
  2. Clinically significant ocular trauma.
  3. Active ocular Herpes simplex or Herpes Zoster infection
  4. Ocular inflammation (uveitis, iritis, scleritis, episcleritis, keratitis, conjunctivitis) at the discretion of the investigator.
  5. Ocular infection (e.g., viral, bacterial, mycobacterial, protozoan or fungal infection or the cornea, conjunctiva, lacrimal gland, lacrimal sac or eyelids including hordeolum/stye).
  6. Active, systemic or local disease condition that causes clinically significant ocular surface irritation such that it could interfere with the questions in the survey and examination findings.
  7. Moderate to severe (Grade 2-4) allergic, vernal or giant papillary conjunctivitis.
  8. Severe (Grade 3 or 4) inflammation of the eyelid (e.g., blepharochalasis, staphylococcal blepharitis or seborrheic blepharitis)
  9. Eyelid abnormalities that significantly affect the lid function (e.g., entropion, ectropion, tumor, edema, blepharospasm, lagophthalmos, severe trichiasis, severe ptosis).
  10. Ocular surface abnormality that may compromise the corneal integrity (e.g., prior chemical burn, recurrent corneal erosion, corneal epithelial defect, Grade 3 corneal fluorescein staining, map dot fingerprint dystrophy, or the effect of any other ophthalmic medication that might in the opinion of the investigator compromise the ocular surface integrity).
  11. Participation in another ophthalmic clinical trial involving a therapeutic drug or device within 30 days prior to enrollment date.
  12. Participation in this trial in the same patient's fellow eye
  13. Patients who are pregnant or breastfeeding or who may become pregnant during participation in the study.

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.